Logo image of ARQT

ARCUTIS BIOTHERAPEUTICS INC (ARQT) Stock Fundamental Analysis

NASDAQ:ARQT - Nasdaq - US03969K1088 - Common Stock - Currency: USD

13.98  +0.32 (+2.34%)

After market: 14.2536 +0.27 (+1.96%)

Fundamental Rating

3

ARQT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. ARQT may be in some trouble as it scores bad on both profitability and health. ARQT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ARQT has reported negative net income.
In the past year ARQT has reported a negative cash flow from operations.
ARQT had negative earnings in each of the past 5 years.
In the past 5 years ARQT always reported negative operating cash flow.
ARQT Yearly Net Income VS EBIT VS OCF VS FCFARQT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -37.70%, ARQT perfoms like the industry average, outperforming 57.58% of the companies in the same industry.
ARQT has a Return On Equity (-90.93%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -37.7%
ROE -90.93%
ROIC N/A
ROA(3y)-62.08%
ROA(5y)-56.46%
ROE(3y)-177.71%
ROE(5y)-130.52%
ROIC(3y)N/A
ROIC(5y)N/A
ARQT Yearly ROA, ROE, ROICARQT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

With an excellent Gross Margin value of 88.39%, ARQT belongs to the best of the industry, outperforming 90.55% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for ARQT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARQT Yearly Profit, Operating, Gross MarginsARQT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

ARQT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARQT has been increased compared to 1 year ago.
ARQT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ARQT has an improved debt to assets ratio.
ARQT Yearly Shares OutstandingARQT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ARQT Yearly Total Debt VS Total AssetsARQT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

ARQT has an Altman-Z score of 0.45. This is a bad value and indicates that ARQT is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 0.45, ARQT is doing good in the industry, outperforming 67.02% of the companies in the same industry.
A Debt/Equity ratio of 0.75 indicates that ARQT is somewhat dependend on debt financing.
The Debt to Equity ratio of ARQT (0.75) is worse than 77.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.75
Debt/FCF N/A
Altman-Z 0.45
ROIC/WACCN/A
WACC10.53%
ARQT Yearly LT Debt VS Equity VS FCFARQT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

ARQT has a Current Ratio of 3.55. This indicates that ARQT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.55, ARQT is in line with its industry, outperforming 42.25% of the companies in the same industry.
A Quick Ratio of 3.37 indicates that ARQT has no problem at all paying its short term obligations.
ARQT has a Quick ratio (3.37) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.55
Quick Ratio 3.37
ARQT Yearly Current Assets VS Current LiabilitesARQT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 64.51% over the past year.
The Revenue has grown by 100.03% in the past year. This is a very strong growth!
EPS 1Y (TTM)64.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
Revenue 1Y (TTM)100.03%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%32.84%

3.2 Future

The Earnings Per Share is expected to grow by 35.63% on average over the next years. This is a very strong growth
ARQT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 35.38% yearly.
EPS Next Y50.68%
EPS Next 2Y46.29%
EPS Next 3Y45%
EPS Next 5Y35.63%
Revenue Next Year67.43%
Revenue Next 2Y51.99%
Revenue Next 3Y46.38%
Revenue Next 5Y35.38%

3.3 Evolution

ARQT Yearly Revenue VS EstimatesARQT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ARQT Yearly EPS VS EstimatesARQT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ARQT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 85.97 indicates a quite expensive valuation of ARQT.
Based on the Price/Forward Earnings ratio, ARQT is valued cheaper than 88.77% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.76, ARQT is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 85.97
ARQT Price Earnings VS Forward Price EarningsARQT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARQT Per share dataARQT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

ARQT's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as ARQT's earnings are expected to grow with 45.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.29%
EPS Next 3Y45%

More info and screens

0

5. Dividend

5.1 Amount

ARQT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCUTIS BIOTHERAPEUTICS INC

NASDAQ:ARQT (5/23/2025, 9:13:53 PM)

After market: 14.2536 +0.27 (+1.96%)

13.98

+0.32 (+2.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-12 2025-08-12
Inst Owners106.65%
Inst Owner Change-2.48%
Ins Owners2.04%
Ins Owner Change1.03%
Market Cap1.67B
Analysts84.62
Price Target21.42 (53.22%)
Short Float %14.07%
Short Ratio6.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.01%
Min EPS beat(2)6.63%
Max EPS beat(2)65.4%
EPS beat(4)4
Avg EPS beat(4)28.69%
Min EPS beat(4)6.63%
Max EPS beat(4)65.4%
EPS beat(8)8
Avg EPS beat(8)25.78%
EPS beat(12)11
Avg EPS beat(12)18.7%
EPS beat(16)15
Avg EPS beat(16)16.25%
Revenue beat(2)2
Avg Revenue beat(2)10%
Min Revenue beat(2)3.7%
Max Revenue beat(2)16.29%
Revenue beat(4)4
Avg Revenue beat(4)10.17%
Min Revenue beat(4)3.7%
Max Revenue beat(4)16.64%
Revenue beat(8)8
Avg Revenue beat(8)39.13%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.7%
PT rev (3m)7.69%
EPS NQ rev (1m)-5.46%
EPS NQ rev (3m)29.73%
EPS NY rev (1m)13.54%
EPS NY rev (3m)32.36%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)4.33%
Revenue NY rev (1m)0.58%
Revenue NY rev (3m)7.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 85.97
P/S 7.83
P/FCF N/A
P/OCF N/A
P/B 11.68
P/tB 13.21
EV/EBITDA N/A
EPS(TTM)-1.04
EYN/A
EPS(NY)0.16
Fwd EY1.16%
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS1.79
BVpS1.2
TBVpS1.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.7%
ROE -90.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.39%
FCFM N/A
ROA(3y)-62.08%
ROA(5y)-56.46%
ROE(3y)-177.71%
ROE(5y)-130.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.75
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 107.04%
Cap/Sales 2.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.55
Quick Ratio 3.37
Altman-Z 0.45
F-Score4
WACC10.53%
ROIC/WACCN/A
Cap/Depr(3y)909.75%
Cap/Depr(5y)643.63%
Cap/Sales(3y)211.41%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
EPS Next Y50.68%
EPS Next 2Y46.29%
EPS Next 3Y45%
EPS Next 5Y35.63%
Revenue 1Y (TTM)100.03%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%32.84%
Revenue Next Year67.43%
Revenue Next 2Y51.99%
Revenue Next 3Y46.38%
Revenue Next 5Y35.38%
EBIT growth 1Y38.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.93%
EBIT Next 3Y37.44%
EBIT Next 5Y32.75%
FCF growth 1Y61.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.53%
OCF growth 3YN/A
OCF growth 5YN/A